openPR Logo
Press release

Vascular Disrupting Agents Market Report on Size, Share, Scope and Forecast 2024-2031

02-03-2024 10:31 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: InsightAce Analytic Pvt.Ltd

/ PR Agency: InsightAce Analytic Pvt.Ltd
Vascular Disrupting Agents Market Report on Size, Share, Scope

Vascular Disrupting Agents Market worth $2.25 billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Vascular Disrupting Agents Market By Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Liver Cancer, Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer , Renal Pelvis, and Ureter Cancer), Therapeutic Area (Hematological Malignancies, Solid Tumors), Molecules (Tubulin Binding Agents, Flavonoids, Ligand-Directed Agents), Therapy (Mono, Combination), Route of Administration (Oral, Intravenous), Product (Bavituximab, Icaritin, NGR-TNF, Padeliporfin, Plinabulin, VB-111, and Others))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
According to the latest research by InsightAce Analytic, the global vascular disrupting agents market is valued at US$ 79.75 million in 2021, and it is expected to reach US$ 2256.41 million by 2030, with a CAGR of 46.7% during the forecast period of 2022-2030.
Get Free Sample Copy of Report : https://www.insightaceanalytic.com/request-sample/1299
Vascular disruption agents (VDAs) are a novel category of drugs targeting tumours' blood supply. VDAs vary conceptually and operationally from currently utilized antiangiogenic medicines and exhibit high selectivity for established but aberrant tumour vasculature. Vascular disrupting agents are novel anticancer compounds with better efficacy and less toxicity. The vascular disrupting agents target the formed tumour vasculature and disrupt blood flow to cancerous tissue. These agents are currently being used for the treatment of different oncology conditions.
The high prevalence of various cancer types, growing geriatric population, fast adoption of anticancer therapies, rising patient awareness regarding the advantages of targeted therapies, increasing oncology expenditure, and rising demand for personalized drugs are expected to drive the vascular disrupting agents market during the forecast period. According to the WHO, cancer is among the leading causes of death worldwide. In 2020, estimated mortalities were 10 million and projected to reach 13 million by 2030. Further, many new anticancer therapies are being developed for various cancers (mainly solid tumours), thus offering new opportunities for the vascular disrupting agents market in the forthcoming years. However, the high cost of production and complex manufacturing processes of targeting therapies and unsatisfactory results of clinical trials may restrain the market adoption during the forecast years.
Region-wise, North America is expected to dominate this market during the forecast period. Additionally, the Asia Pacific region is likely to witness maximum growth in the next few years due to the increasing innovations of anticancer drugs & therapies, rising incidences of cancer, and growing demand for advanced therapy options.
Major market players operating in the vascular disrupting agents market include AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VBL Therapeutics (Israel), Steba Biotech (US), BeyondSpring Pharmaceuticals (US), Immune Pharmaceuticals (US), Nereus Pharmaceuticals (US), Madrigal Pharmaceuticals, Inc. (US), Celgene Corporation (US), Bionomics Ltd. (Australia), Lees Pharmaceutical Holdings. (Hong Kong), among others.
Key Developments in the Market:
• In April 2022, VBL Therapeutics stated that the FDA had given ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel Fast Track designation for the treatment of platinum-resistant ovarian cancer. VBL Therapeutics' experimental anticancer, gene-based drug Ofra-vec is being developed to treat a variety of solid tumours. The OVAL Phase 3 registration-enabling trial in patients with recurrent platinum-resistant ovarian cancer is the principal clinical initiative for ofra-vec.
• In December 2021, The US Food and Drug Administration (FDA) sent a comprehensive response letter (CRL) in response to BeyondSpring Pharmaceuticals' new drug application (NDA) requesting approval of plinabulin combined with granulocyte colony-stimulating factor (G-CSF) to prevent chemotherapy-induced neutropenia (CIN).
• In June 2021, VBL Therapeutics (Israel) provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) for platinum-resistant treatment ovarian cancer.
• In March 2021, Steba Biotech, Padeliporfin ImPACT was given Orphan Drug Designation (ODD) for treating adult patients with upper tract urothelial cancer (UTUC). The FDA has also granted Padeliporfin ImPACT Fast Track designation for the treatment of adult patients with low-grade and unifocal high-grade UTUC.
• In January 2021, Bionomics Limited, a biopharmaceutical company, announced that all patients had completed their treatment phase in the MODULATE clinical trial, an experimental Phase 2 trial of BNC105 in combination with Bristol-Myers Squibb's nivolumab (OPDIVO) in patients with metastatic colorectal cancer.
Curious about report? Enquiry before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1299
Market Segments
Global Vascular Disrupting Agents Market, by Indications, 2020-2030 (Valu US$ Mn)
• Chemotherapy-Induced Neutropenia
• Glioblastoma
• Liver Cancer
• Mesothelioma
• Non-Small Cell Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Renal Pelvis
• Ureter Cancer
Global Vascular Disrupting Agents Market, by Therapeutic Area, 2020-2030 (Valu US$ Mn)
• Hematological Malignancies
• Solid Tumors
Global Vascular Disrupting Agents Market, by Molecules, 2020-2030 (Value US$ Mn)
• Tubulin Binding Agents
• Flavonoids
• Ligand-Directed Agents
Global Vascular Disrupting Agents Market, by Therapy, 2020-2030 (Valu US$ Mn)
• Mono
• Combination
Global Vascular Disrupting Agents Market, by Route of Administration, 2020-2030 (Value US$ Mn)
• Oral
• Intravenous
Global Vascular Disrupting Agents Market, by Product, 2020-2030 (Value US$ Mn)
• Bavituximab
• Icaritin
• NGR-TNF
• Padeliporfin
• Plinabulin
• VB-111
• Others
Global Vascular Disrupting Agents Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
 To receive a comprehensive clinical trial/pipeline analysis for the global vascular disrupting agents market
 To receive an industry overview and future trends of the vascular disrupting agents market
 To analyze the vascular disrupting agents market drivers and challenges
 To get information on the vascular disrupting agents market size (Value US$ Mn) forecast to 2030
 To get information for major investments, mergers & acquisitions in the vascular disrupting agents market industry
For More Customization @ https://www.insightaceanalytic.com/customisation/1299

Other Related Reports Published by InsightAce Analytic:
Global Multiple Cancer Monoclonal Antibodies Market
Global Cancer Biosimilars Market
Global Head and Neck Cancer Market
Global Immuno-Oncology Cell Therapy Market
Global iPSCs Manufacturing Services Market

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vascular Disrupting Agents Market Report on Size, Share, Scope and Forecast 2024-2031 here

News-ID: 3371650 • Views:

More Releases from InsightAce Analytic Pvt.Ltd

AI In The Credit-Scoring Market Smarter Credit Decisions: How AI is Transforming Credit Scoring and Financial Inclusion
AI In The Credit-Scoring Market Smarter Credit Decisions: How AI is Transforming …
AI In The Credit-Scoring Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI In The Credit-Scoring Market - (By Component (Software and Service), By Application (Personal Credit Scoring and Corporate Credit Scoring), By Industry Vertical (BFSI (Banking, Financial Services, Insurance), Retail, Healthcare, Telecommunications, Utilities, and Real Estate)), Trends,
Surgical Robotics Simulation Market Guiding the Next Generation of Surgeons: Growth and Trends in the Surgical Robotics Simulation Market
Surgical Robotics Simulation Market Guiding the Next Generation of Surgeons: Gro …
Surgical Robotics Simulation Market Worth $1,283.6 Mn by 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Surgical Robotics Simulation Market Size, Share & Trends Analysis Report By Product Type (Product, Services), By Application (General Surgery, Gynecological Surgery, Urological Surgery, Neurological Surgery (Head and Neck Surgery), Cardiological Surgery, Orthopedic Surgery, Others), By End User (Hospitals, Ambulatory Surgical Centers,
AI Studio Market Accelerating Innovation: The Benefits of AI Studios for Businesses
AI Studio Market Accelerating Innovation: The Benefits of AI Studios for Busines …
Global AI Studio Market Worth $57.89 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI Studio Market- (By Application (Sentiment Analysis, Customer Service Automation, Image Classification & Labelling, Synthetic Data Generation, Predictive Modelling & Forecasting, Automatic Content Generation, and Others), By Offering, By Vertical, By Region, Trends, Industry Competition Analysis, Revenue and Forecast
Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Growing Cells, Growing Hope: The Potential of hiPSCs in Preclinical Disease Modeling and Market Expansion
Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market G …
Global Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market- (Disease (Neurological Disorders and Dystrophies, Cardiac disorders, Retinal Eye Disease, Metabolic Disorders, Liver disease, Others), Products and Services (Disease Model, Reprogramming service, Differentiation

All 5 Releases


More Releases for Agents

AGENTS CO., LTD. Launches Early TDAC Application Made Simple by AGENTS
AGENTS CO., LTD. has launched a dedicated platform for submitting Thailand Digital Arrival Cards (TDAC), built specifically to support travel agents, tour operators, and travel service providers managing group travel. The system is designed to eliminate the stress of last-minute filings and make the TDAC process faster, more flexible, and more reliable for everyone involved. One of the platform's standout features is its support for full pre-submission edits, allowing agents to
Anti-parathyroid Agents Market - Harmony Within Reach: Anti-parathyroid Agents D …
Newark, New Castle, USA: The "Anti-parathyroid Agents Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Anti-parathyroid Agents Market: https://www.growthplusreports.com/report/antiparathyroid-agents-market/8935 This latest report researches the industry structure, sales, revenue,
Hypertensive Crisis Agents Market - Empowering Emergency Response: Hypertensive …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Hypertensive Crisis Agents Market. Hypertensive Crisis Agents Market: https://www.growthplusreports.com/report/hypertensive-crisis-agents-market/9142 The Hypertensive Crisis Agents Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the
Tocolytic Agents Market - Preserving Pregnancy, Ensuring Wellbeing: Tocolytic Ag …
Newark, New Castle, USA - new report, titled Tocolytic Agents Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Tocolytic Agents market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Tocolytic Agents market. The report offers an overview of the market, which
uParcel Launches 'Agents Benefits' for their Delivery Agents
uParcel announced today the launch of Agent Benefits for new and current verified delivery agents which aims to expand the existing network of Delivery Agents Team. Through the Agents Benefits launches, uParcel hopes to increase the number of delivery agent signups to fulfil the increasing numbers of delivery jobs. uParcel believes in long-term investment in the delivery agents' job welfare and well-being. "We're not looking for a short-term partnership with
Global Packaging Additives Market - By product (Antimicrobial Agents, Antifog Ag …
Market Research Reports Search Engine (MRRSE) has recently updated its massive report catalog by adding a fresh study titled “Global Packaging Additives Market - In-Depth Analysis with Booming Trends Supporting Growth and Forecast till 2028”. This business intelligence study encapsulates vital details about the market current as well as future status during the mentioned forecast period of 2028. The report also targets important facets such as market drivers, challenges, latest